CA2149242C — Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
Assigned to Pfizer Inc · Expires 1998-08-04 · 28y expired
What this patent protects
This invention relates to the quinuclidine derivative (2S,3S)-N-(5-n-propyl-2-me thoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo¢2.2.2!octan-3-amine and its pharmaceutically acceptable salts. Thes e compounds are substance P antagonists and are useful in the treatment of gastroi…
USPTO Abstract
This invention relates to the quinuclidine derivative (2S,3S)-N-(5-n-propyl-2-me thoxyphenyl)methyl-2-diphenylmethyl-1-azabicyclo¢2.2.2!octan-3-amine and its pharmaceutically acceptable salts. Thes e compounds are substance P antagonists and are useful in the treatment of gastrointestinal disorders, inflamatory disorders , central nervous system disorders and pain.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.